Financial updates
Pharming Group reports third quarter 2023 financial results
Pharming Group N.V. presents its preliminary, unaudited financial report for the three months ended September 30, 2023.
-
Third quarter 2023 revenues increased 23% to US$66.7 million, compared to the third quarter 2022, driven by RUCONEST® revenue and the U.S. commercial launch of Joenja®
-
Nine month year to date 2023 revenues increased 9% to US$164.1 million, compared to nine month year to date 2022
-
RUCONEST® revenues increased 11% in the third quarter 2023 to US$60.2 million, compared to the third quarter 2022, and increased 18% compared to the second quarter 2023
-
RUCONEST® nine month year to date 2023 revenues increased by 2% YoY; on track for low single digit annual revenue growth
-
Continued strength in U.S. Joenja® (leniolisib) launch during the third quarter 2023; 63 patients on paid therapy and US$6.5 million revenue
-
Overall cash and marketable securities of US$199.2 million at the end of the third quarter 2023, compared to US$194.1 million at the end of the second quarter 2023
Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 EDT on October 26, 2023 (view webcast).To participate in the conference call, please register in advance using this link